Upozornění: Text přílohy byl získán strojově a nemusí přesně odpovídat originálu. Zejména u strojově nečitelných smluv, kde jsme použili OCR. originál smlouvy stáhnete odsud
ASSIGNMENT AND ASSUMPTION
OF
INVESTIGATOR-INITIATED RESEARCH AGREEMENT
THIS ASSIGNMENT AND ASSUMPTION AGREEMENT is valid as of the date of last
signature and shall come into effect as of the date of its publication in the Register of
Contracts pursuant to the Act No. 340/2015 Coll., on Special Terms for Effectiveness ofSome
Contracts, Publishing of such Contracts in the Register of Contracts and for the Register of
Contracts, as amended (“Effective Date") by and among Regeneron Pharmaceuticals, Inc., a
New York corporation, located at 777 Old Saw Mill River Road, Tarrytown, New York 10591-
6707 ("Regeneron“) ("Assignor"), Sanofi-Aventis, s.r.o., located at Evropská 846/176a,
Postal Code: 16000, Prague 6 — Vokovice, Czech Republic, Indentification Number: 44848200
("Sanofi") ("Assignee"), Institute for Clinical and Experimental Medicine located at
Vídeňská 1958/9, Prague 4, 14021, Czech Republic, Indentification Number: 00023001
("Institution"), and NEOX s.r.o. located at Pancířova 196/2, Prague 4, 14300 Czech Republic,
Identification Number: 62917927 (“CRO"), and shall amend the Investigator-Initiated
Research Agreement (defined below].
WHEREAS, Institution, CRO, and Regeneron have entered into an Investigator-Initiated
Research Agreement as of September 5, 2019 (the "Agreement");
WHEREAS, Assignor wishes to assign all of its rights, obligations, liabilities and
interests in the Agreement to the Assignee, and Institution and CRO are willing to consent to
such assignment, subject to the terms and conditions set forth below.
NOW, THEREFORE, the parties agree as follows:
1. Effective as of April 1“, 2020, Assignor hereby assigns all of its rights, obligations,
liabilities and interests in the Agreement to Assignee.
2. Effective as of April 1“, 2020, Assignee hereby accepts such assignment, agrees to be
bound by all the terms of the Agreement, and assumes all of the responsibilities,
obligations, liabilities ofAssignor under the Agreement.
3. Assignee, Institution, and CRO further agree that all references to Assignor in the
Agreement are hereby amended to refer to Assignee. It is understood and agreed that
all other provisions ofthe Agreement shall remain in full force and effect.
4. In consideration of this Assignment and Assumption Agreement, the parties hereto
agree that Assignor shall be relieved of all obligations to perform under the Agreement.
Assignor shall remain fully liable for performance of its obligations prior to April lst,
2020 only.
Assignee's representative for the purpose ofreceiving legal notices shall until further
notice be:
sanofi-aventis, s.r.o.
Evropská 846/176a,
Postal Code: 16000, Prague 6 — Vokovice, Czech Republic
Assignee's representative for the administration of invoices shall until further notice
be:
sanofi-aventis, s.r.o.
Evropská 846/176a,
Postal Code: 16000, Prague 6 — Vokovice, Czech Republic
This Assignment and Assumption Agreement may be executed in one or more
counterparts, each of which is an original and all of which constitute the Assignment
and Assumption Agreement.
All capitalized terms used but not defined herein shall have the meaning ascribed to
them in the Agreement.
Except as expressly amended by this Assignment and Assumption Agreement, the
Agreement shall be unchanged and shall remain in full force and effect in accordance
with its terms.
10. For the sake of clarity, the parties expressly agree that the provisions of this
Assignment and Assumption Agreement shall also apply to the parties from April 1st
2020 until and after the Effective Date ofthis Assignment and Assumption Agreement.
-Signatures on Next Page—
IN WITNESS WHEREOF, the parties have hereby executed this Assignment and Assumption
Agreement by their duly authorized representatives as of the Effective Date.
By: _
N ame-
Exec Dir Medical Affairs Operations
Title:
Date: Jul 15, 2020
Approved as to legal policy
per Regeneron Policy #950
Sanofi-Aventis, s.r.
By:
Name: Ro „LW ŠŠŠ l 4:61
Title: PM“! WL 1’52
Date: JL ?. 1°20
Title: 5. 10. 2020
Date:
NEOX
Name: f all, ‘ '" ‘ “\
Title:
Date: “ “'“